01—Abstract
Summary
Summary of the 8-K filed April 8, 2026. Cited figures are marked; the original filing is the authoritative source.
Regeneron Pharmaceuticals, Inc. (REGN) has filed a Form 8-K to disclose anticipated financial results for the first quarter of 2026.
The company expects to record an acquired in-process research and development (IPR&D) charge of approximately $102 milliona on a pre-tax basis. This charge is primarily associated with equity securities purchased and payments made under collaboration and licensing agreements. The most significant impact for investors is the expected negative effect of this IPR&D charge on both GAAP and non-GAAP net income per diluted share, estimated at $0.81 for the first quarter of 2026.
It's important to note that these are preliminary estimates, subject to finalization of financial closing procedures, and actual results could differ. The company also highlighted that acquired IPR&D charges are inherently unpredictable and not typically forecasted.
02—Key points
Key Highlights
- Anticipated $102 million pre-tax acquired IPR&D charge for Q1 2026.
- Charge primarily relates to equity securities and collaboration/licensing agreement payments.
- Expected negative impact of $0.81 per diluted share on both GAAP and non-GAAP net income for Q1 2026.
- Preliminary financial information; actual results may vary.
- Acquired IPR&D charges are unpredictable and not forecasted by the company.
- The company provides context on its use of non-GAAP financial measures.
03—Questions
Frequently Asked Questions
What is the primary reason for the expected charge in Q1 2026?
The primary reason for the anticipated charge is related to acquired in-process research and development (IPR&D), specifically involving premiums on equity securities purchased and up-front or milestone payments associated with collaboration and licensing agreements.
How will this charge impact Regeneron's earnings per share?
Regeneron expects this acquired IPR&D charge to negatively impact its net income per diluted share by approximately $0.81 for the first quarter of 2026, affecting both GAAP and non-GAAP measures.
Are these final results for Q1 2026?
No, these are preliminary estimates. The financial results for the first quarter of 2026 have not been finalized and are subject to the company's financial statement closing procedures. Actual results may differ from these preliminary estimates.
Why doesn't Regeneron forecast acquired IPR&D charges?
Regeneron does not forecast acquired IPR&D charges because their occurrence, magnitude, and timing are uncertain and depend on future transactions, making them unpredictable.
04—Continue